Research programme: anti-bacterial therapeutics - Smartbax
Latest Information Update: 09 Jun 2023
At a glance
- Originator Technical University Munich
- Developer smartbax
- Class Antibacterials; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections
Most Recent Events
- 29 May 2023 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in Germany (unspecified route) (Smartbax website, May 2023)
- 29 May 2023 Preclinical trials in Vancomycin-resistant enterococcal infections in Germany (unspecified route) (Smartbax website, May 2023)